Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Abstract

The immunotherapeutic agent ipilimumab has helped address a significant unmet need in the treatment of advanced melanoma. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4), thereby augmenting antitumor immune responses. After decades in which a number of clinical trials were conducted, ipilimumab was the first therapy to improve overall survival in a randomized, controlled phase III trial of patients with advanced melanoma. These results led to the regulatory approval of ipilimumab at 3 mg/kg for the treatment of unresectable or metastatic melanoma. More than 17,000 patients worldwide have received ipilimumab, either as a commercial drug at 3 mg/kg or in clinical trials and expanded access programs at different doses. Consistent with its proposed mechanism of action, the most common toxicities associated with ipilimumab therapy are inflammatory in nature. These immune‐related adverse events were mostly reversible when effective treatment guidelines were followed. Importantly, long‐term follow‐up of patients who received ipilimumab in a phase III trial showed that 24% survived at least two years, and in phase II studies, a proportion of patients survived at least five years. Evaluation of ipilimumab is ongoing in the adjuvant setting for melanoma, and for advanced disease in nonsmall cell lung, small cell lung, prostate, ovarian, and gastric cancers.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 91

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010;60::277-300.

   Not in our library10.3322/caac.20073

3. 3.

   Korn EL, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 2008;26::527-534.

   Not in our library10.1200/jco.2007.12.7837

4. 4.

   Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future perspectives. Oncologist. 2011;16::5-24.

   Not in our library10.1634/theoncologist.2010-0190

5. 5.

   Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastases: a literature review. Cancer Control. 2009;16::248-255.

   Not in our library10.1177/107327480901600307

6. 6.

   Agarwala SS. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res. 2010;20::1-10.

   Not in our library10.1097/cmr.0b013e328333bbc8

7. 7.

   Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur. J. Cancer. 2004;40::1825-1836.

   Not in our library10.1016/j.ejca.2004.04.030

8. 8.

   Rosenberg SA. Raising the bar: the curative potential of human caner immunotherapy. Sci. Transl. Med. 2012;4::127ps8.

   Not in our library10.1126/scitranslmed.3003634

9. 9.

   Eggermont AM. Advances in systemic treatment of melanoma. Ann. Oncol. 2010;21(Suppl 7)):vii339-vii344.

   Not in our library10.1093/annonc/mdq364

10. 10.

    Hoos A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 2010;37::533-546.

    Not in our library10.1053/j.seminoncol.2010.09.015

11. 11.

    Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer. 2011;11::805-812.

    Not in our library10.1038/nrc3153

12. 12.

    Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy. 2013;5::215-229.

    Not in our library10.2217/imt.13.9

13. 13.

    Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363::711-723.

    Not in our library10.1056/nejmoa1003466

14. 14.

    Robert C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011;364::2517-2526.

    Not in our library10.1056/nejmoa1104621

15. 15.

    Ribas A, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013;31::616-622.

    Not in our library10.1200/jco.2012.44.6112

16. 16.

    Hoos A, et al. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010;102::1388-1397.

    Not in our library10.1093/jnci/djq310

17. 17.

    Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur. J. Cancer. 2011;47::2150-2157.

    Not in our library10.1016/j.ejca.2011.06.052

18. 18.

    Shaw HM, Nathan PD. Vemurafenib in melanoma. Expert Rev. Anticancer Ther. 2013;13::513-522.

    Not in our library10.1586/era.13.24

19. 19.

    McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop. J. 2006;26::154-158.

    Not in our library

20. 20.

    Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res. 2009;69::5269-5284.

    Not in our library10.1158/0008-5472.can-09-1750

21. 21.

    Waldmann TA. Immunotherapy: past, present and future. Nat. Med. 2003;9::269-277.

    Not in our library10.1038/nm0303-269

22. 22.

    Burnett FM. The concept of immunological surveillance. Prog. Exp. Tumor Res. 1970;13::1-27.

    Not in our library10.1159/000386035

23. 23.

    Lockyer CR, Gillatt DA. BCG immunotherapy for superficial bladder cancer. J. R. Soc. Med. 2001;94::119-123.

    Not in our library10.1177/014107680109400305

24. 24.

    Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 2012;23(Suppl 8)):viii6-viii9.

    Not in our library10.1093/annonc/mds256

25. 25.

    Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer. 2007;7::95-106.

    Not in our library10.1038/nrc2051

26. 26.

    Visser de KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer. 2006;6::24-37.

    Not in our library10.1038/nrc1782

27. 27.

    Abrams SI. Regulation of tumor progression by anti-neoplastic T cell responses. Cancer Biol. Ther. 2004;3::140-146.

    Not in our library10.4161/cbt.3.2.758

28. 28.

    Caligiuri MA. Human natural killer cells. Blood. 2008;112::461-469.

    Not in our library10.1182/blood-2007-09-077438

29. 29.

    Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 2006;90::297-339.

    Not in our library10.1016/s0065-2776(06)90008-x

30. 30.

    Blackburn SD, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009;10::29-37.

    Not in our library10.1038/ni.1679

31. 31.

    DeVita VT, Rosenberg SA. Two hundred years of cancer research. N. Engl. J. Med. 2012;366::2207-2214.

    Not in our library10.1056/nejmra1204479

32. 32.

    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144::646-647.

    Not in our library10.1016/j.cell.2011.02.013

33. 33.

    Finn OJ. Cancer immunology. N. Engl. J. Med. 2008;358::2704-2715.

    Not in our library10.1056/nejmra072739

34. 34.

    Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 2007;17::275-287.

    Not in our library10.1016/j.semcancer.2007.06.009

35. 35.

    Hoos A, Britten CM, Huber C, O'Donnell-Tormey J. A methodological framework to enhance the clinical success of cancer immunotherapy. Nat. Biotechnol. 2011;29::867-870.

    Not in our library10.1038/nbt.2000

36. 36.

    Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science. 1995;270::932-933.

    Not in our library10.1126/science.270.5238.932

37. 37.

    Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996;183::2533-2540.

    Not in our library10.1084/jem.183.6.2533

38. 38.

    Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 2006;18::206-213.

    Not in our library10.1016/j.coi.2006.01.011

39. 39.

    Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Oncol. Targets Ther. 2010;3::15-25.

    Not in our library10.2147/ott.s4833

40. 40.

    Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995;182::459-465.

    Not in our library10.1084/jem.182.2.459

Cited by papers we hold 6

• Current Advances in the Treatment of BRAF-Mutant Melanoma · 2020
  No notice
• Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab · 2018
  No notice
• CD4 and CD8 T lymphocyte interplay in controlling tumor growth · 2017
  No notice
• Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology · 2016
  Corrected
• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment · 2014
  No notice
• Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort · 2014
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.